The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer

References

• Banerjee S, Gore M. The future of targeted therapies in ovarian cancer. Oncologist 2009;14:706-16
   PubMed Web of Science ®Google Scholar
• Jain R. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 2005;19:7-16
   PubMedGoogle Scholar
• Byrne A, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9(15):5721-8
   PubMed Web of Science ®Google Scholar
• Akagi Y, Liu W, Zebrowski B, et al. Regulation of vascular endothelial growth factor expansion in human colon cancer by insulin-like growth factor-I. Cancer Res 1998;58(17):4008-14
   Google Scholar
• Nasu R, Kimura H, Akagi K, et al. Blood flow influences vascular growth during tumour angiogenesis. Br J Cancer 1999;79(5-6):780-6
   Google Scholar
• Hicklin DJ, Ellis LM. Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-27
   PubMed Web of Science ®Google Scholar
• Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005;23(6):1295-311
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76
   PubMed Web of Science ®Google Scholar
• Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus of vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002;9(Suppl 2):36-44
   PubMedGoogle Scholar
• Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235(4787):442-7
   PubMed Web of Science ®Google Scholar
• Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161(2):851-8
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362(6423):841-4
   PubMed Web of Science ®Google Scholar
• Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cell Signal 2007;19(10):2003-12
   PubMed Web of Science ®Google Scholar
• Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65(3):671-80
   PubMed Web of Science ®Google Scholar
• Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004;38(7-8):1258-64
   PubMed Web of Science ®Google Scholar
• AVASTIN^® package insert. Genetech, Inc; CA, USA: 2004
   Google Scholar
• US FDA. Highlights of prescribing information for AVASTIN®. 2004. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2013/125085s263lbl.pdf
   Google Scholar
• AVASTIN^® product monograph. Hoffman-La Roche Limited; ON, Canada: 2005
   Google Scholar
• Lin YS, Nguyen C, Mendoza JL, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999;288(1):371-8
   PubMed Web of Science ®Google Scholar
• Augustin HG. Translating angiogenesis research into the clinic: the challenges ahead. Br J Radiol 2003;76(Spec. No. 1):S3-S10
   Google Scholar
• Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165
   PubMed Web of Science ®Google Scholar
• Cannistra S, Mathulonis U, Penson R, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-6
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Brookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank S, Goff B, et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-45
   PubMed Web of Science ®Google Scholar
• Carboplatin, paclitaxel and gemcitabine with or without bevacizumab after surgery in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer. Available from: http://clinicaltrials.gov/show/NCT00565851 [Last accessed 18 March 2013]
   Google Scholar
• Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19(3):843-50
   PubMed Web of Science ®Google Scholar
• Ranpura V, Pulipati B, Chu D, et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010;23(5):460-8
   PubMed Web of Science ®Google Scholar
• Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010;21(8):1381-9
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2004;22(11):2184-91
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010;49(3):287-97
   PubMed Web of Science ®Google Scholar
• Shord SS, Bressler LR, Tierney LA, et al. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 2009;66(11):999-1013
   PubMed Web of Science ®Google Scholar
• AVASTIN^® prescribing information. Gentech Inc; CA, USA: 2011
   Google Scholar
• George Sledge KM, Novotny W, Gaudreault J, et al. A Phase II trial of single-agent rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proc Am Soc Clin Oncol 2000;19
   Google Scholar
• Han E, Monk B. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007;105(1):3-6
   PubMed Web of Science ®Google Scholar
• Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metromonic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76
   PubMed Web of Science ®Google Scholar
• Nimeiri HS, Oza AM, Morgan RJ, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian cancer primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2008;110:49
   PubMed Web of Science ®Google Scholar
• Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009;10:559
   PubMed Web of Science ®Google Scholar
• Diaz JP, Tew WP, Zivanovic O, et al. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecol Oncol 2010;116:335
   PubMed Web of Science ®Google Scholar
• Richardson DL, Backes FJ, Hurt JD, et al. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol 2010;118:47
   PubMed Web of Science ®Google Scholar
• Drugstore. Available from: www.drugstore.com
   Google Scholar
• NICE. Available from: www.nice.org.uk
   Google Scholar
• Cohn DE, Kim KH, Resnick KE, et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011;29(10):1247-51
   PubMed Web of Science ®Google Scholar
• Chan J, Herzog T, Hu L, et al. A cost effective strategy of bevacizumab in treatment of primary ovarian cancer–A subset analysis of ICON7 trial. Presented at the 43rd Annual Meeting of the Society of Gynecologic Oncology; 24-27 March 2012. Austin, TX: Gynecol Oncol 2012. 125:S1-S188. Abstract 39
   Google Scholar
• Stuart GC, Kitchener H, Bacon M, et al. Gynecologic cancer intergroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011 21:750-5
   Google Scholar
• McGuire W, Hoskins W, Brady M, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996;334:1-6
   PubMed Web of Science ®Google Scholar
• Ozols R, Bundy B, Greer B, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200
   PubMed Web of Science ®Google Scholar
• A Phase III randomized controlled clinical trial of carboplatin and paclitaxel (or gemcitabine) alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreduction surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer. NCI-supplied agents: bevacizumab. Protocol GOG-0213. Revised 2012. Available from: http://www.dukecancerinstitute.org/research/clinical-trials/00007487
   Google Scholar
• Schilder R, Sill M, Lankes H, et al. A phase II evaluation on motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol 2013;129:86-91
   PubMed Web of Science ®Google Scholar
• Karlan B, Oza A, Richardson G, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012;30:362-71
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang L, Hao Q. Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Gynecol Oncol 2013;288(2):367-74
   Google Scholar
• Dean E, Middleton MR, Pwint T, et al. Phase I study to assess the safety and tolerability of Olaparib in combination with Bevacizumab in patients with advanced solid tumours. Br J Cancer 2012;106(3):468-74
   PubMed Web of Science ®Google Scholar
• Markman M, Bundy B, Alberts D, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clini Oncol 2001;19:1001-7
   PubMed Web of Science ®Google Scholar
• Fagotti A, Costantani B, Petrillo M, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol Oncol 2012;127(3):502-5
   PubMed Web of Science ®Google Scholar